March 28, 2024

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Key Points

Key points are not available for this paper at this time.

Abstract

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Mikhail Kosiborod

Mark C. Petrie

Barry A. Borlaug

Journals

New England Journal of Medicine

Actions

Institutions

University of Missouri–Kansas City

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study